ClinicalTrials.gg

Program

SRX246

Its studies are mostly in Fragile X Syndrome · Disruptive, Impulse Control, and Conduct Disorders · Huntington Disease · Stress Disorders, Post-Traumatic · Anxiety Disorders, led by Azevan Pharmaceuticals.

Furthest: phase 2, since Feb 3, 20147 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Azevan Pharmaceuticals71 open or runningphase 2since Feb 3, 2014May 27, 2009Dec 2027phase 2 · NCT07328529

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2009First study: phase 1 study in HealthyFirst studyNCT00910455 · 49 enrolled · United States
  2. Mar 15, 2010Phase 1 study in HealthyNCT01088932 · 24 enrolled · United States
  3. Feb 3, 2014Phase 2 study in Disruptive, Impulse Control, and Conduct DisordersNCT02055638 · 97 enrolled · United States
  4. Jul 22, 2015Phase 2 study in Huntington DiseaseNCT02507284 · 106 enrolled · United States
  5. Mar 29, 2016Phase 2 study in Stress Disorders, Post-TraumaticNCT02733614 · 33 enrolled · United States
  6. Sep 29, 2016Phase 1 study in Anxiety DisordersNCT02922166 · 36 enrolled · United States
  7. Jan 7, 2026Phase 2 study in Fragile X SyndromeNCT07328529 · 80 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 2 study in Fragile X SyndromeNCT07328529

TargetBeta

AVPR1A →read by rule
“Vasopressin V1a receptor antagonist”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07328529Fragile X Syndrome · United States2Not yet recruitingDec 202780
NCT02922166Anxiety Disorders · United States1UNKNOWNMay 10, 201936
NCT02733614Stress Disorders, Post-Traumatic · United States2TerminatedOct 202033
NCT02507284Huntington Disease · United States2CompletedSep 10, 2018106
NCT02055638Disruptive, Impulse Control, and Conduct Disorders · United States2CompletedMay 201697
NCT01088932Healthy · United States1CompletedJun 201024
NCT00910455Healthy · United States1CompletedSep 200949

How it is read

Names in the registry

  • “SRX246”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
SRX246 (Azevan Pharmaceuticals): development program | ClinicalTrials.gg